November 8, 2012 / 7:56 PM / 5 years ago

BRIEF-Cardiovascular risk for Novo nordisk's degludec insulin uncertain: chair of FDA panel

1 Min Read

Nov 8 (Reuters) - Novo Nordisk A/S : * FDA advisory panel acting chairperson says panel members generally agree that signal of cardiovascular risk was seen for Novo nordisk's

degludec insulin, and that it "may or may not be real" risk

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below